title: Severe deafness associated with Crohn's disease and spondylarthropathy: successful treatment with anti-TNF.
authors.forename: Marie
authors.initials: M
authors.lastname: Jachiet
authors.forename: Claire
authors.initials: C
authors.lastname: Lependu
authors.forename: Dorothée
authors.initials: D
authors.lastname: Fragny
authors.forename: Xavier
authors.initials: X
authors.lastname: Mariette
authors.forename: Christine
authors.initials: C
authors.lastname: Lepajolec
authors.forename: Raphaèle
authors.initials: R
authors.lastname: Seror
mesh_terms: D000068879:Adalimumab; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D003424:Crohn Disease / Q000150:complications / Q000188:drug therapy*; D003638:Deafness / Q000150:complications / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D005938:Glucocorticoids / Q000627:therapeutic use; D006319:Hearing Loss, Sensorineural / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use; D011241:Prednisone / Q000627:therapeutic use; D025242:Spondylarthropathies / Q000150:complications / Q000188:drug therapy*; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*; D055815:Young Adult
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D005938:Glucocorticoids; D014409:Tumor Necrosis Factor-alpha; D000068879:Adalimumab; D011241:Prednisone; D008727:Methotrexate